A three-dimensional quantitative structure-activity analysis of a new class of bisphenol topoisomerase IIα inhibitors

Molecular Pharmacology

Volumn 73, Issue 3, 2008, Pages 686-696

  Liang, Hong ^a   Wu, Xing ^a   Yalowich, Jack C ^b   Hasinoff, Brian B ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4,4' ISOPROPYLIDENEDIPHENOL; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR;

ARTICLE; CATALYSIS; CELL GROWTH; CELL STRAIN K 562; COMPARATIVE MOLECULAR FIELD ANALYSIS; COMPARATIVE MOLECULAR SIMILARITY INDICES ANALYSIS; DRUG ACTIVITY; DRUG SYNTHESIS; GROWTH INHIBITION; HUMAN; HUMAN CELL; HYDROGEN BOND; HYDROPHOBICITY; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CATALYSIS; CHO CELLS; CRICETINAE; CRICETULUS; DNA; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; ELECTROSTATICS; ENZYME INHIBITORS; ETOPOSIDE; HUMANS; HYDROGEN BONDING; HYDROPHOBICITY; INHIBITORY CONCENTRATION 50; K562 CELLS; LEUKEMIA, ERYTHROBLASTIC, ACUTE; MODELS, CHEMICAL; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NUCLEIC ACID CONFORMATION; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RAZOXANE;

EID: 40849092787     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.107.041624     Document Type: Article

References (35)

1. Akimitsu N, Adachi N, Hirai H, Hossain MS, Hamamoto H, Kobayashi M, Aratani Y, Koyama H, and Sekimizu K (2003) Enforced cytokinesis without complete nuclear division in embryonic cells depleting the activity of DNA topoisomerase II. Genes Cells 8:393-402.
2. Andoh T and Ishida R (1998) Catalytic inhibitors of topoisomerase II. Biochim Biophys Acta 1400:155-171.
3. Burden DA, Froelich-Ammon SJ, and Osheroff N (2001) Topoisomerase II-mediated cleavage of plasmid DNA. Methods Mol Biol 95:283-289.
4. Classen S, Olland S, and Berger JM (2003) Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187 [published erratum appears in Proc Natl Acad Sci U S A 100:14510, 2003]. Proc Natl Acad Sci U S A 100:10629-10634.
5. Cramer RD 3rd, Patterson DE, and Bunce JD (1988) Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J Am Chem Soc 110:5959-5967.
6. Fattman C, Allan WP, Hasinoff BB, and Yalowich JC (1996) Collateral sensitivity to the bisdioxopiperazine dexrazoxane (ICRF-187) in etoposide (VP-16) resistant human leukemia K562 cells. Biochem Pharmacol 52:635-642.
7. Fortune JM and Osheroff N (2000) Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice. Prog Nucleic Acid Res Mol Biol 64:221-253.
8. Gewirtz DA (1999) A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57:727-741.
9. Hasinoff BB, Kuschak TI, Creighton AM, Fattman CL, Allan WP, Thampatty P, and Yalowich JC (1997) Characterization of a Chinese hamster ovary cell line with acquired resistance to the bisdioxopiperazine dexrazoxane (ICRF-187) catalytic inhibitor of topoisomerase II. Biochem Pharmacol 53:1843-1853.
10. Hasinoff BB, Kuschak TI, Yalowich JC, and Creighton AM (1995) A QSAR study comparing the cytotoxicity and DNA topoisomerase II inhibitory effects of bisdioxopiperazine analogs of ICRF-187 (dexrazoxane). Biochem Pharmacol 50:953-958.
11. Hasinoff BB, Wu X, Begleiter A, Guziec L, Guziec F, Giorgianni A, Yang S, Jiang Y, and Yalowich JC (2006) Structure-activity study of the interaction of bioreductive benzoquinone alkylating agents with DNA topoisomerase II. Cancer Chemother Pharmacol 57:221-233.
12. Hasinoff BB, Wu X, Krokhin OV, Ens W, Standing KG, Nitiss JL, Sivaram T, Giorgianni A, Yang S, Jiang Y, et al. (2005) Biochemical and proteomics approaches to characterize topoisomerase IIα cysteines and DNA as targets responsible for cisplatin-induced inhibition of topoisomerase IIα. Mol Pharmacol 67:937-947.
13. 2(levrazoxane), of the topoisomerase II inhibitors dexrazoxane (ICRF-187) and levrazoxane (ICRF-186). J Inorg Biochem 98:616-624.
14. Hasinoff BB, Yalowich JC, Ling Y, and Buss JL (1996) The effect of dexrazoxane (ICRF-187) on doxorubicin- and daunorubicin-mediated growth inhibition of Chinese hamster ovary cells. Anticancer Drugs 7:558-567.
15. Holm B, Sehested M, and Jensen PB (1998) Improved targeting of brain tumors using dexrazoxane rescue of topoisomerase II combined with supralethal doses of etoposide and teniposide. Clin Cancer Res 4:1367-1373.
16. Ishida R, Miki T, Narita T, Yui R, Sato M, Utsumi KR, Tanabe K, and Andoh T (1991) Inhibition of intracellular topoisomerase II by antitumor bis(2,6-dioxopiperazine) derivatives: mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors. Cancer Res 51:4909-4916.
17. Jensen LH, Liang H, Shoemaker RH, Grauslund M, Sehested M, and Hasinoff BB (2006) A three-dimensional quantitative structure-activity relationship study of the inhibition of the ATPase activity and the strand passing catalytic activity of topoisomerase IIα by substituted purine analogs. Mol Pharmacol 70:1503-1513.
18. Jensen LH, Thougaard AV, Grauslund M, Sokilde B, Carstensen EV, Dvinge HK, Scudiero DA, Jensen PB, Shoemaker RH, and Sehested M (2005) Substituted purine analogues define a novel structural class of catalytic topoisomerase II inhibitors. Cancer Res 65:7470-7477.
19. Jensen PB and Sehested M (1997a) DNA topoisomerase II rescue by catalytic inhibitors. Biochem Pharmacol 54:755-759.
20. Jensen PB and Sehested M (1997b) DNA topoisomerase II rescue by catalytic inhibitors: a new strategy to improve the antitumor selectivity of etoposide. Biochem Pharmacol 54:755-759.
21. Klebe G, Abraham U, and Mietzner T (1994) Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J Med Chem 37:4130-4146.
22. Kubinyi H, Hamprecht FA, and Mietzner T (1998) Three-dimensional quantitative similarity-activity relationships (3D QSiAR) from SEAL similarity matrices. J Med Chem 41:2553-2564.
23. Larsen AK, Escargueil AE, and Skladanowski A (2003) Catalytic topoisomerase II inhibitors in cancer therapy. Pharmacol Ther 99:167-181.
24. Li TK and Liu LF (2001) Tumor cell death induced by topoisomerase- targeting drugs. Annu Rev Pharmacol Toxicol 41:53-77.
25. Liang H, Wu X, Guziec LJ, Guziec FSJ, Larson KK, Lang J, Yalowich JC, and Hasinoff BB (2006) A structure-based 3D-QSAR study of anthrapyrazole analogs of the anticancer agents losoxantrone and piroxantrone. J Chem Inf Model 46:1827-1835.
26. Pommier Y, Pourquier P, Fan Y, and Strumberg D (1998) Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim Biophys Acta 1400:83-106.
27. Priebe W, Fokt I, Przewloka T, Chaires JB, Portugal J, and Trent JO (2001) Exploiting anthracycline scaffold for designing DNA-targeting agents. Methods Enzymol 340:529-555.
28. Ritke MK, Allan WP, Fattman C, Gunduz NN, and Yalowich JC (1994a) Reduced phosphorylation of topoisomerase II in etoposide-resistant human leukemia K562 cells. Mol Pharmacol 46:58-66.
29. Ritke MK, Roberts D, Allan WP, Raymond J, Bergoltz VV, and Yalowich JC (1994b) Altered stability of etoposide-induced topoisomerase II-DNA complexes in resistant human leukaemia K562 cells. Br J Cancer 69:687-697.
30. Sehested M, Jensen PB, Sorensen BS, Holm B, Friche E, and Demant EJF (1993) Antagonistic effect of the cardioprotector (+)-1,2-bis(3,5- dioxopiperazinyl-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16). Biochem Pharmacol 46:389-393.
31. Tanabe K, Ikegami Y, Ishida R, and Andoh T (1991) Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives. Cancer Res 51:4903-4908.
32. Wang JC (2002) Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol 3:430-440.
33. Wilstermann AM and Osheroff N (2003) Stabilization of eukaryotic topoisomerase II-DNA cleavage complexes. Curr Top Med Chem 3:321-338.
34. Wu X and Hasinoff BB (2005) The antitumor anthracyclines doxorubicin and daunorubicin do not inhibit cell growth through the formation of iron-mediated reactive oxygen species. Anticancer Drugs 16:93-99.
35. Zhang H, D'Arpa P, and Liu LF (1990) A model for tumor cell killing by topoisomerase poisons. Cancer Cells 2:23-27.